Andy Studna, Editor

Valued up to $100 million, the collaboration will conduct clinical trials over a five-year period with the goal of strengthening decentralized models.

In the fifth and final part of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA shares what excites her most about the future of clinical technology.

Incyte’s Monjuvi (tafasitamab) met its primary endpoint of progression free survival in the study.

In part 4 of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA highlights how the regulators are addressing new technology with updated guidances.

In part 3 of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA touches on how the right technology for your study should alleviate site burden and improve data quality.

In part 2 of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA discusses how advancements in technology are creating challenges with integration and how they can be addressed.

In part 1 of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA highlights how patients, sites, and sponsors can benefit from recent advancements such as AI and LLMs.

In the fourth and final part of this video interview, Vincent Keunen, founder & CEO of Andaman7 looks forward and highlights some potential advancements with the use of AI.

In part 3 of this video interview, Vincent Keunen, founder & CEO of Andaman7 shares his own experience as a patient when it comes to using digital applications.

Patients in the Keytruda (pembrolizumab)-vibostolimab combo plus chemotherapy arm experienced a higher rate of adverse events compared to those in the control arm.

In part 2 of this video interview, Vincent Keunen, founder & CEO of Andaman7 highlights how technology vendors should be keeping the patient in mind when building solutions.

In a presentation at the 2024 International Association for the Study of Pain World Congress, Concentric Analgesics shared positive Phase II data for its lead candidate.

In part 1 of this video interview, Vincent Keunen, founder & CEO of Andaman7 discusses how service providers and sponsors can make the lives of patients contributing to research easier.

Phase III study of Bayer’s non-steroidal, selective mineralocorticoid receptor antagonist met its primary endpoint.

In the fifth and final part of this video interview, Rama Kondru, PhD, CEO of Veridix AI looks forward to what the LLM landscape in clinical trials could look like in five years.

Phase III study of tirzepatide in adults with heart failure with preserved ejection fraction and obesity met all primary endpoints.

In part 4 of this video interview, Rama Kondru, PhD, CEO of Veridix AI discusses best practices for choosing the right artificial intelligence solutions.

In part 3 of this video interview, Rama Kondru, PhD, CEO of Veridix AI touches on how large language models can leverage unstructured data.

The trial demonstrated clinically meaningful improvements in overall response rate and duration of response in its patient population.

In part 2 of this video interview, Rama Kondru, PhD, CEO of Veridix AI highlights areas that large language models can be used in clinical trials including patient recruitment and retention.

According to the trial data, PGN-EDO51 is outperforming previously studied oligonucleotide therapies.

In part 1 of this video interview, Rama Kondru, PhD, CEO of Veridix AI discusses challenges with adoption and the potential uses of large language models in clinical trials.

AstraZeneca’s CALQUENCE (acalabrutinib) in combination with venetoclax, with or without obinutuzumab achieved the significant and clinically meaningful improvement in the AMPLIFY Phase III trial.

The CETP inhibitor lowered low-density lipoprotein cholesterol by 36.3% at day 84 and 41.5% at day 365 compared to placebo.

Positive trial results show the specialized cell product achieved an overall slowing of disease worsening compared to placebo.

In the fifth and final part of this video interview, Carie Pierce, SVP, global head of growth & business development, DIA touches on how the organization continues to break down silos in clinical research and provide a medium for collaboration.

Pfizer’s giroctocogene fitelparvovec reduced annualized bleeding rate in participants from week 12 up to at least 15 months and achieved superiority compared to prophylaxis.

In part 4 of this video interview, Carie Pierce, SVP, global head of growth & business development, DIA discusses how the organization is looking to expand into different global regions and continue leading awareness for the clinical research industry.

The investigational prophylactic monoclonal antibody met its primary endpoints, reducing infections up to day-150.

In part 3 of this video interview, Carie Pierce, SVP, global head of growth & business development, DIA highlights the most relevant themes related to clinical trials that were present at DIA including DE&I and patient recruitment.